<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Argenica Therapeutics Ltd — News on 6ix</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd</link>
<description>Latest news and press releases for Argenica Therapeutics Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 01:34:07 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/argenica-therapeutics-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836624278dffbe2df15c4c0.webp</url>
<title>Argenica Therapeutics Ltd</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd</link>
</image>
<item>
<title>Presentations at European Stroke Organisation Conference</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/presentations-at-european-stroke-organisation-conference</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/presentations-at-european-stroke-organisation-conference</guid>
<pubDate>Thu, 26 Mar 2026 01:34:07 GMT</pubDate>
<description>Presentations at European Stroke Organisation Conference</description>
</item>
<item>
<title>Argenica Receives $3.97m R&D Tax Incentive Cash Rebate</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/argenica-receives-dollar397m-randd-tax-incentive-cash-rebate</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/argenica-receives-dollar397m-randd-tax-incentive-cash-rebate</guid>
<pubDate>Tue, 17 Mar 2026 01:40:08 GMT</pubDate>
<description>Argenica Receives $3.97m R&D Tax Incentive Cash Rebate</description>
</item>
<item>
<title>Half Yearly Report and Accounts</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/half-yearly-report-and-accounts-347</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/half-yearly-report-and-accounts-347</guid>
<pubDate>Wed, 11 Feb 2026 02:38:25 GMT</pubDate>
<description>Half Yearly Report and Accounts</description>
</item>
<item>
<title>Successful Applicaton for EMA Paediatric Waiver</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/successful-applicaton-for-ema-paediatric-waiver</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/successful-applicaton-for-ema-paediatric-waiver</guid>
<pubDate>Mon, 02 Feb 2026 03:22:06 GMT</pubDate>
<description>Successful Applicaton for EMA Paediatric Waiver</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-120</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-120</guid>
<pubDate>Wed, 28 Jan 2026 02:36:08 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/brainomix-ai-technology-reveals-efficacy-of-novel-neuroprotective-drug-candidate-in-severe-acute-ischemic-stroke-patients</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/brainomix-ai-technology-reveals-efficacy-of-novel-neuroprotective-drug-candidate-in-severe-acute-ischemic-stroke-patients</guid>
<pubDate>Thu, 18 Dec 2025 09:00:00 GMT</pubDate>
<description>Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, today announced results from its partnership with Argenica Therapeutics (ASX: AGN) for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke. Analysis using Brainomix 360 Stroke, an FDA-cleared and CE-marked AI-imaging platform, confirmed statistically significant and clinically meaningful efficacy of ARG-007 in severe acut</description>
</item>
<item>
<title>AI Analysis Reveals Efficacy In Severe Stroke Patients</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/ai-analysis-reveals-efficacy-in-severe-stroke-patients</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/ai-analysis-reveals-efficacy-in-severe-stroke-patients</guid>
<pubDate>Thu, 11 Dec 2025 03:32:06 GMT</pubDate>
<description>AI Analysis Reveals Efficacy In Severe Stroke Patients</description>
</item>
<item>
<title>Positive TNK Study Results Fulfil Key FDA Requirement</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/positive-tnk-study-results-fulfil-key-fda-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/positive-tnk-study-results-fulfil-key-fda-requirement</guid>
<pubDate>Thu, 04 Dec 2025 02:38:09 GMT</pubDate>
<description>Positive TNK Study Results Fulfil Key FDA Requirement</description>
</item>
<item>
<title>ARG-007 Efficacious Dose Validated in New Preclinical Study</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/arg-007-efficacious-dose-validated-in-new-preclinical-study</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/arg-007-efficacious-dose-validated-in-new-preclinical-study</guid>
<pubDate>Tue, 25 Nov 2025 03:37:06 GMT</pubDate>
<description>ARG-007 Efficacious Dose Validated in New Preclinical Study</description>
</item>
<item>
<title>Phase 2 Trial Promising Improvements in Functional Outcomes</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/phase-2-trial-promising-improvements-in-functional-outcomes</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/phase-2-trial-promising-improvements-in-functional-outcomes</guid>
<pubDate>Wed, 15 Oct 2025 01:48:28 GMT</pubDate>
<description>Phase 2 Trial Promising Improvements in Functional Outcomes</description>
</item>
<item>
<title>Topline Phase 2 Trial Results of ARG-007 in AIS Patients</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/topline-phase-2-trial-results-of-arg-007-in-ais-patients</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/topline-phase-2-trial-results-of-arg-007-in-ais-patients</guid>
<pubDate>Wed, 03 Sep 2025 03:55:12 GMT</pubDate>
<description>Topline Phase 2 Trial Results of ARG-007 in AIS Patients</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/trading-halt-823</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/trading-halt-823</guid>
<pubDate>Mon, 01 Sep 2025 03:21:13 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Appendix 4E & Annual Report to 30 June 2025</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/appendix-4e-and-annual-report-to-30-june-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/appendix-4e-and-annual-report-to-30-june-2025-1</guid>
<pubDate>Thu, 28 Aug 2025 11:25:14 GMT</pubDate>
<description>Appendix 4E & Annual Report to 30 June 2025</description>
</item>
<item>
<title>Argenica Receives IND Feedback From FDA</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/argenica-receives-ind-feedback-from-fda</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/argenica-receives-ind-feedback-from-fda</guid>
<pubDate>Thu, 14 Aug 2025 03:28:28 GMT</pubDate>
<description>Argenica Receives IND Feedback From FDA</description>
</item>
<item>
<title>Argenica Awarded Federal Government Funding</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/argenica-awarded-federal-government-funding</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/argenica-awarded-federal-government-funding</guid>
<pubDate>Fri, 20 Jun 2025 04:14:11 GMT</pubDate>
<description>Argenica Awarded Federal Government Funding</description>
</item>
<item>
<title>Argenica to Progress Clinical Development in TBI</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/argenica-to-progress-clinical-development-in-tbi</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/argenica-to-progress-clinical-development-in-tbi</guid>
<pubDate>Wed, 18 Jun 2025 03:10:09 GMT</pubDate>
<description>Argenica to Progress Clinical Development in TBI</description>
</item>
<item>
<title>Update on Investigational New Drug Application</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/update-on-investigational-new-drug-application</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/update-on-investigational-new-drug-application</guid>
<pubDate>Tue, 10 Jun 2025 03:03:17 GMT</pubDate>
<description>Update on Investigational New Drug Application</description>
</item>
<item>
<title>New US Patent for Surgical Stroke</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/new-us-patent-for-surgical-stroke</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/new-us-patent-for-surgical-stroke</guid>
<pubDate>Thu, 22 May 2025 02:41:06 GMT</pubDate>
<description>New US Patent for Surgical Stroke</description>
</item>
<item>
<title>Last Patient Dosed in Phase 2 Stroke Trial</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/last-patient-dosed-in-phase-2-stroke-trial</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/last-patient-dosed-in-phase-2-stroke-trial</guid>
<pubDate>Fri, 11 Apr 2025 02:42:29 GMT</pubDate>
<description>Last Patient Dosed in Phase 2 Stroke Trial</description>
</item>
<item>
<title>Updated - Main TBI Injury Study Annoucement</title>
<link>https://6ix.com/company/argenica-therapeutics-ltd/news/updated-main-tbi-injury-study-annoucement</link>
<guid isPermaLink="true">https://6ix.com/company/argenica-therapeutics-ltd/news/updated-main-tbi-injury-study-annoucement</guid>
<pubDate>Tue, 04 Feb 2025 04:29:10 GMT</pubDate>
<description>Updated - Main TBI Injury Study Annoucement</description>
</item>
</channel>
</rss>